ev3 — Merger or Acquisition (June 2009)
19 slides from ev3's merger presentation, Jun 3, 2009
Slide 1: ev3 and Chestnut Medical Proposed Acquisition
ev3 and Chestnut Medical Proposed Acquisition June 2, 2009
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements contained in this presentation that relate to future, not past, events are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the expected timing of ev3's acqui
Slide 3: Use of Non-GAAP Financial Measures
Use of Non-GAAP Financial Measures To supplement ev3's consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), ev3 uses certain non- GAAP financial measures in this presentation, such as "non-GAAP EPS." Although ev3 typically provides recon
Slide 4: Overview: Chestnut Medical Technologies, Inc.
Overview Chestnut Medical Technologies, Inc. Founded to pioneer new minimally invasive therapies for interventional neuroradiology Chestnut's mission is to develop technologies that are easier to use while improving outcomes and reducing complications in the treatment of neurovascular disease Headqu
Slide 5: Transaction Highlights
Transaction Highlights Chestnut Medical Technologies, Inc. Consideration up to $150M Total upfront consideration of $75M payable at closing, with 30% to 40% in cash and remainder in ev3 common stock Additional milestone-based contingent payment of up to $75M payable in a combination of cash and ev3
Slide 6: Chestnut Medical is an Excellent Fit
Chestnut Medical is an Excellent Fit Chestnut Medical transaction reinforces ev3's commitment to neurovascular division ev3's fastest growing division (5-year CAGR of 41%) Pipeline gross margin expected to be consistent with, or better than, the current gross margin of ev3's neuro business Pipeline
Slide 7: Chestnut's Products
Chestnut's Products Innovative flow diversion device to treat cerebral aneurysms "Intravascular" vs "Intrasaccular" treatment approach CE Mark; U.S. IDE studies underway Pipeline Embolization Device (PED) Foreign body retrieval technology Allows for positive and direct grasping and tactile feedback
Slide 8: Significant Unmet Clinical Need in Treating Challenging Aneurysms
Significant Unmet Clinical Need in Treating Challenging Aneurysms Current therapy options include surgical clipping or bypass and endovascular coiling and stent-assisted coiling Current therapy options not effective in treating large & giant, wide-neck or non- saccular aneurysms Incomplete aneurysm
Slide 9: Pipeline Embolization Device: The Future of Aneurysm Treatment
Pipeline Embolization Device: The Future of Aneurysm Treatment Extends endovascular treatment into large market segment with significant unmet clinical need Large & giant, wide-neck and other challenging aneurysms that currently are not well treated with either surgical or endovascular techniques Ma
Slide 10: Significant Market Opportunity for Pipeline Solution
49% (2) 42,000 Market Opportunity Procedures 42,000 Procedure ASP $8,200-$8,500 Avg. Implants / Procedure 1.5 ev3 estimates; Worldwide aneurysm procedures suitable for endovascular treatment in 2013; excludes ruptured aneurysms Assumed treatable with flow diversion device (large & giant, wide-neck,
Slide 11: Pipeline: How it Works
Pipeline: How it Works Self-expanding, microcatheter-delivered, cylindrical mesh "Flow Diversion" device Designed to: 1) divert blood flow away from the aneurysm sac 2) assist in reconstruction of the parent artery 3) while leaving the side vessels open Investigational Use Only: Not FDA approved or
Slide 12: Why Pipeline Flow Diversion vs Stenting?
Why Pipeline Flow Diversion vs Stenting? Pipeline Flow Diversion Neuro Stents Able to navigate and conform to curved vasculature +++ +/++ Flow alteration +++ + Coil or embolic retention +++ ++ Supports intimal growth across neck of aneurysm +++ + Deliverability +++ ++/+++ Radiopacity / Visibility ++
Slide 13: Very Favorable Early Physician Experience
Very Favorable Early Physician Experience "We have done five aneurysms with Pipeline yesterday and today. It was certainly impressive. They improved the technology a lot, they have a new deployment catheter which is great and also new pusher and a second generation design. It is definitely the way t
Slide 14: Pipeline Case Example #1: Standalone Treatment of Aneurysm
Pre-Treatment 1 month Follow-Up Pipeline Case Example #1: Standalone Treatment of Aneurysm Post-Treatment Investigational Use Only: Not FDA approved or cleared
Slide 15: Pipeline Case Example #2: Treatment of Recurring Aneurysm after Coiling
6 month Follow-Up Post-Treatment Pre-Treatment Pipeline Case Example #2: Treatment of Recurring Aneurysm after Coiling Investigational Use Only: Not FDA approved or cleared
Slide 16: Pipeline Selected Clinical References
Pipeline Selected Clinical References Lylyk P, et al: Curative endovascular reconstruction of cerebral aneurysms with the Pipeline Embolization Device: The Buenos Aires Experience. Neurosurgery 64:632- 643, 2009. Access article at: www.pubmed.gov Conclusion: "Endovascular reconstruction with the PED
Slide 17: Pipeline Clinical Study Overview
Pipeline Clinical Study Overview 300+ patients treated to date with the Pipeline device PITA Study ("Pipeline for Intracranial Treatment of Aneurysms") Conducted at 4 centers, N=31 6-month study with clinical and radiographic follow-up Effectiveness: 93% complete occlusion at 6 mo; 100% occluded at
Slide 18: In Summary: Chestnut Medical is an Excellent Fit
In Summary: Chestnut Medical is an Excellent Fit Complementary growth platform that fits our mission - broadens product portfolio for aneurysm treatment and offers first-mover advantage in flow diversion devices Compelling initial published clinical data compared to existing treatment alternatives P
Slide 19: ev3 and Chestnut Medical Proposed Acquisition
ev3 and Chestnut Medical Proposed Acquisition June 2, 2009